Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFC-Containing Albuterol Phase-Out Review To Begin January 2003

Executive Summary

FDA will begin the phase-out process for CFC-containing albuterol and beclomethasone products after Jan. 20, 2003, when its final rule on ozone-depleting substances goes into effect
Advertisement

Related Content

Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access
Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access
Albuterol CFC Phase-Out Date Needed Now For HFA Ramp Up, Firms Says
Albuterol CFC Phase-Out Date Needed Now For HFA Ramp Up, Firms Says
CFC Albuterol Inhaler Phase-Out Urged By Nine Groups In Citizen Petition
CFC Albuterol Inhaler Phase-Out Urged By Nine Groups In Citizen Petition
FDA Generics Review Staff To Increase 25% In President’s Budget Request
FDA Pediatric Drug Division Director Will Be GSK’s Shirley Murphy
CFC-Free Inhalers Would Not Need To Replace All Strengths – FDA Final Rule
CFC-Free Inhalers Would Not Need To Replace All Strengths – FDA Final Rule
Advertisement
UsernamePublicRestriction

Register

PS040215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel